CCM
ADPT icon

CAAS Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

CAAS Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-180,431
Closed -$10.7M – 1130
2020
Q4 		$10.7M Buy
+180,431
New +$9.3M 0.1% 191

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

CAAS Capital Management's ADPT Position: Q1 2021 in Review

CAAS Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2021, closing a stake of 180,431 shares — an estimated $10.7M sold.

CAAS Capital Management first reported a position in ADPT in Q4 2020 and held it in 1 quarter. The position peaked at $10.7M in Q4 2020. 248 funds tracked by Wall St. Rank hold ADPT as of Q1 2021.

  • CAAS Capital Management reported no remaining Adaptive Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 180,431 Adaptive Biotechnologies shares in Q1 2021, an estimated $10.7M.
  • CAAS Capital Management first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Adaptive Biotechnologies position peaked at $10.7M in Q4 2020.
  • 248 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.